DNA vaccine-derived human IgG produced in transchromosomal bovines protect in lethal models of hantavirus pulmonary syndrome

Science Translational Medicine

Volumn 6, Issue 264, 2014, Pages

  Hooper, Jay W ^a   Brocato, Rebecca L ^a   Kwilas, Steven A ^a   Hammerbeck, Christopher D ^a   Josleyn, Matthew D ^a   Royals, Michael ^b   Ballantyne, John ^c   Wu, Hua ^d   Jiao, Jin An ^d   Matsushita, Hiroaki ^d   Sullivan, Eddie J ^b  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b Cedar Industries   (United States)

^c Aldevron LLC   (United States)

^d SAB Biotherapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; IMMUNOGLOBULIN G ANTIBODY; NEUTRALIZING ANTIBODY; POLYCLONAL ANTIBODY; POLYCLONAL IMMUNOGLOBULIN ANTIBODY; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G;

ANDES VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CATTLE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HANTAVIRUS; HANTAVIRUS PULMONARY SYNDROME; JET INJECTION; LOW DRUG DOSE; NONHUMAN; POST EXPOSURE PROPHYLAXIS; SIN NOMBRE VIRUS; SYRIAN HAMSTER; VIRION; ANIMAL; BIOAVAILABILITY; BIOSYNTHESIS; BOVINE; DISEASE MODEL; HAMSTER; HUMAN; IMMUNOLOGY; TRANSGENIC ANIMAL; VACCINATION; VIROLOGY;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; BIOLOGICAL AVAILABILITY; CATTLE; CRICETINAE; DISEASE MODELS, ANIMAL; FEMALE; HANTAVIRUS; HANTAVIRUS PULMONARY SYNDROME; HUMANS; IMMUNOGLOBULIN G; SIN NOMBRE VIRUS; VACCINATION; VACCINES, DNA;

EID: 84914128755     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3010082     Document Type: Article

References (50)

1. Centers for Disease Control and Prevention (CDC), Update: Outbreak of hantavirus infection - Southwestern United States, 1993. MMWR Morb. Mortal. Wkly. Rep. 42, 495-496 (1993).
2. A. S. Khan, J. C. Young, Hantavirus pulmonary syndrome: At the crossroads. Curr. Opin. Infect. Dis. 14, 205-209 (2001).
3. C. Schmaljohn, Vaccines for hantaviruses. Vaccine 27 (Suppl. 4), D61-D64 (2009).
4. B. Knust, P. E. Rollin, Twenty-year summary of surveillance for human hantavirus infections, United States. Emerg. Infect. Dis. 19, 1934-1937 (2013).
5. K. B. Nolte, R. M. Feddersen, K. Foucar, S. R. Zaki, F. T. Koster, D. Madar, T. L. Merlin, P. J. McFeeley, E. T. Umland, R. E. Zumwalt, Hantavirus pulmonary syndrome in the United States: A pathological description of a disease caused by a new agent. Hum. Pathol. 26, 110-120 (1995).
6. S. R. Zaki, P. W. Greer, L. M. Coffield, C. S. Goldsmith, K. B. Nolte, K. Foucar, R. M. Feddersen, R. E. Zumwalt, G. L. Miller, A. S. Khan, P. E. Rollin, T. G. Ksiazek, S. T. Nichol, B. W. J. Mahy, C. J. Peters, Hantavirus pulmonary syndrome. Pathogenesis of an emerging infectious disease. Am. J. Pathol. 146, 552-579 (1995).
7. P. A. Vial, F. Valdivieso, G. Mertz, C. Castillo, E. Belmar, I. Delgado, M. Tapia, M. Ferrés, Incubation period of hantavirus cardiopulmonary syndrome. Emerg. Infect. Dis. 12, 1271-1273 (2006).
8. J. C. Young, G. R. Hansen, T. K. Graves, M. P. Deasy, J. G. Humphreys, C. L. Fritz, K. L. Gorham, A. S. Khan, T. G. Ksiazek, K. B. Metzger, C. J. Peters, The incubation period of hantavirus pulmonary syndrome. Am. J. Trop. Med. Hyg. 62, 714-717 (2000).
9. C. D. Hammerbeck, J. W. Hooper, in New Generation Vaccines, M. M. Levine, Ed. (Informa Healthcare, New York, 2010), vol. 1, chap. 83, pp. 905-913.
10. C. Schmaljohn, S. T. Nichol, in Fields Virology, D. M. Knipe, P. M. Howley, Eds. (Lippincott, Williams, and Wilkins, Philadelphia, PA, 2006), pp. 1741-1789.
11. R. Brocato, M. Josleyn, J. Ballantyne, P. Vial, J. W. Hooper, DNA vaccine-generated duck polyclonal antibodies as a postexposure prophylactic to prevent hantavirus pulmonary syndrome (HPS). PLOS One 7, e35996 (2012).
12. J. W. Hooper, D. M. Custer, J. Smith, V. Wahl-Jensen, Hantaan/Andes virus DNA vaccine elicits a broadly cross-reactive neutralizing antibody response in nonhuman primates. Virology 347, 208-216 (2006).
13. J. W. Hooper, M. Josleyn, J. Ballantyne, R. Brocato, A novel Sin Nombre virus DNA vaccine and its inclusion in a candidate pan-hantavirus vaccine against hantavirus pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS). Vaccine 31, 4314-4321 (2013).
14. D. M. Custer, E. Thompson, C. S. Schmaljohn, T. G. Ksiazek, J. W. Hooper, Active and passive vaccination against hantavirus pulmonary syndrome with Andes virus M genome segmentbased DNA vaccine. J. Virol. 77, 9894-9905 (2003).
15. R. L. Brocato, C. D. Hammerbeck, T. M. Bell, J. B. Wells, L. A. Queen, J. W. Hooper, A lethal disease model for hantavirus pulmonary syndrome in immunosuppressed Syrian hamsters infected with Sin Nombre virus. J. Virol. 88, 811-819 (2014).
16. J. W. Hooper, A. M. Ferro, V. Wahl-Jensen, Immune serum produced by DNA vaccination protects hamsters against lethal respiratory challenge with Andes virus. J. Virol. 82, 1332-1338 (2008).
17. V. P. Martinez, C. Bellomo, J. San Juan, D. Pinna, R. Forlenza, M. Elder, P. J. Padula, Person-to-person transmission of Andes virus. Emerg. Infect. Dis. 11, 1848-1853 (2005).
18. P. J. Padula, A. Edelstein, S. D. Miguel, N. M. López, C. M. Rossi, R. D. Rabinovich, Hantavirus pulmonary syndrome outbreak in Argentina: Molecular evidence for person-to-person transmission of Andes virus. Virology 241, 323-330 (1998).
19. P. Vial, F. Valdivieso, M. Calvo, M. L. Rioseco, R. Riquelme, A. Araneda, V. Tomicic, J. Graf, A. Cuiza, C. Marco, C. Vial, B. Hjelle, C. Ye, D. Hanfelt-Goade, J. Rivera, M. Ferres, H. Figueroa, L. Paredes, M. Florenzano, T. Bidart, I. Delgado, G. J. Mertz, A non-randomized multicentre trial of human immune plasma for treatment of hantavirus cardiopulmonary syndrome by ANDV. Antivir. Ther. 10.3851/IMP2875 (2014).
20. Centers for Disease Control and Prevention (CDC), Hantavirus pulmonary syndrome in visitors to a national park-Yosemite Valley, California, 2012. MMWR Morb. Mortal. Wkly. Rep. 61, 952 (2012).
21. J. J. Núñez, C. L. Fritz, B. Knust, D. Buttke, B. Enge, M. G. Novak, V. Kramer, L. Osadebe, S. Messenger, C. G. Albariño, U. Ströher, M. Niemela, B. R. Amman, D. Wong, C. R. Manning, S. T. Nichol, P. E. Rollin, D. Xia, J. P. Watt, D. J. Vugia; Yosemite Hantavirus Outbreak Investigation Team, Hantavirus infections among overnight visitors to Yosemite National Park, California, USA, 2012. Emerg. Infect. Dis. 20, 386-393 (2014).
22. A. Sano, H. Matsushita, H. Wu, J. A. Jiao, P. Kasinathan, E. J. Sullivan, Z. Wang, Y. Kuroiwa, Physiological level production of antigen-specific human immunoglobulin in cloned transchromosomic cattle. PLOS One 8, e78119 (2013).
23. J. W. Hooper, T. Larsen, D. M. Custer, C. S. Schmaljohn, A lethal disease model for hantavirus pulmonary syndrome. Virology 289, 6-14 (2001).
24. H. A. Christian, The Principles and Practice of Medicine (D. Appleton-Century Company Inc., New York, 1944).
25. C. E. Kummerfeldt, Raxibacumab: Potential role in the treatment of inhalational anthrax. Infect. Drug Resist. 7, 101-109 (2014).
26. J. M. Reichert, Antibodies to watch in 2014: Mid-year update. MAbs 6, 799-802 (2014).
27. A. Trkola, H. Kuster, P. Rusert, B. Joos, M. Fischer, C. Leemann, A. Manrique, M. Huber, M. Rehr, A. Oxenius, R. Weber, G. Stiegler, B. Vcelar, H. Katinger, L. Aceto, H. F. Günthard, Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11, 615-622 (2005).
28. G. G. Olinger Jr., J. Pettitt, D. Kim, C. Working, O. Bohorov, B. Bratcher, E. Hiatt, S. D. Hume, A. K. Johnson, J. Morton, M. Pauly, K. J. Whaley, C. M. Lear, J. E. Biggins, C. Scully, L. Hensley, L. Zeitlin, Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc. Natl. Acad. Sci. U.S.A. 109, 18030-18035 (2012).
29. J. Pettitt, L. Zeitlin, H. Kim do, C. Working, J. C. Johnson, O. Bohorov, B. Bratcher, E. Hiatt, S. D. Hume, A. K. Johnson, J. Morton, M. H. Pauly, K. J. Whaley, M. F. Ingram, A. Zovanyi, M. Heinrich, A. Piper, J. Zelko, G. G. Olinger, Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci. Transl. Med. 5, 199ra113 (2013).
30. X. Qiu, J. Audet, G. Wong, S. Pillet, A. Bello, T. Cabral, J. E. Strong, F. Plummer, C. R. Corbett, J. B. Alimonti, G. P. Kobinger, Successful treatment of Ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci. Transl. Med. 4, 138ra81 (2012).
31. J. A. Wilson, M. Hevey, R. Bakken, S. Guest, M. Bray, A. L. Schmaljohn, M. K. Hart, Epitopes involved in antibody-mediated protection from Ebola virus. Science 287, 1664-1666 (2000).
32. L. Bielory, P. Gascon, T. J. Lawley, N. S. Young, M. M. Frank, Human serum sickness: A prospective analysis of 35 patients treated with equine anti-thymocyte globulin for bone marrow failure. Medicine 67, 40-57 (1988).
33. R. F. Clark, S. Wethern-Kestner, M. V. Vance, R. Gerkin, Clinical presentation and treatment of black widow spider envenomation: A review of 163 cases. Ann. Emerg. Med. 21, 782-787 (1992).
34. E. D. Deeks, G. M. Keating, Rabbit antithymocyte globulin (thymoglobulin): A review of its use in the prevention and treatment of acute renal allograft rejection. Drugs 69, 1483-1512 (2009).
35. Centers for Disease Control and Prevention (CDC), Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. MMWR Morb. Mortal. Wkly. Rep. 59, 299 (2010).
36. R. C. Dart, J. McNally, Efficacy, safety, and use of snake antivenoms in the United States. Ann. Emerg. Med. 37, 181-188 (2001).
37. C. H. Kirkpatrick, Allergic histories and reactions of patients treated with digoxin immune Fab (ovine) antibody. The Digibind Study Advisory Panel. Am. J. Emerg. Med. 9, 7-10; discussion 33-14 (1991).
38. S. S. Seddik, S. Wanas, A. Shehata, S. Fawaz, M. H. Helmy, Development of an improved method for production of antiscorpion F(ab¢)2 fragment of IgG with high yield and potency. J. Nat. Toxins 11, 123-132 (2002).
39. S. Kwilas, J. Kishimori, M. Josleyn, K. Jerke, J. Ballantyne, M. Royals, J. W. Hooper, A hantavirus pulmonary syndrome (HPS) DNA vaccine delivered using a spring-powered jet injector elicits a potent neutralizing antibody response in rabbits and nonhuman primates. Curr. Gene Ther. 14, 200-210 (2014).
40. S. Y. Ko, A. Pegu, R. S. Rudicell, Z. Y. Yang, M. G. Joyce, X. Chen, K. Wang, S. Bao, T. D. Kraemer, T. Rath, M. Zeng, S. D. Schmidt, J. P. Todd, S. R. Penzak, K. O. Saunders, M. C. Nason, A. T. Haase, S. S. Rao, R. S. Blumberg, J. R. Mascola, G. J. Nabel, Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 514, 642-645 (2014).
41. A. Casadevall, Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg. Infect. Dis. 8, 833-841 (2002).
42. D. Safronetz, J. Prescott, F. Feldman, E. Haddock, R. Rosenke, A. Okumura, D. Brining, E. Dahlstrom, S. F. Porcella, E. Ebihara, D. P. Scott, B. Hjelle, H. Feldmann., Pathophysiology of hantavirus pulmonary syndrome in rhesus macaques. Proc. Natl. Acad. Sci. U.S.A. 111, 7114-7119 (2014).
43. K. S. Brown, D. Safronetz, A. Marzi, H. Ebihara, H. Feldmann, Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus. J. Virol. 85, 12781-12791 (2011).
44. V. Wahl-Jensen, J. Chapman, L. Asher, R. Fisher, M. Zimmerman, T. Larsen, J. W. Hooper, Temporal analysis of Andes virus and Sin Nombre virus infections of Syrian hamsters. J. Virol. 81, 7449-7462 (2007).
45. N. Ray, J. Whidby, S. Stewart, J. W. Hooper, A. Bertolotti-Ciarlet, Study of Andes virus entry and neutralization using a pseudovirion system. J. Virol. Methods 163, 416-423 (2010).
46. H. Matsushita, A. Sano, H. Wu, J. A. Jiao, P. Kasinathan, E. J. Sullivan, Z. Wang, Y. Kuroiwa, Triple immunoglobulin gene knockout transchromosomic cattle: Bovine lambda cluster deletion and its effect on fully human polyclonal antibody production. PLOS One 9, e90383 (2014).
47. J. W. Hooper, K. I. Kamrud, F. Elgh, D. Custer, C. S. Schmaljohn, DNA vaccination with hantavirus M segment elicits neutralizing antibodies and protects against Seoul virus infection. Virology 255, 269-278 (1999).
48. F. Elgh, A. Lundkvist, O. A. Alexeyev, H. Stenlund, T. Avsic-Zupanc, B. Hjelle, H. W. Lee, K. J. Smith, R. Vainionpää, D. Wiger, G. Wadell, P. Juto, Serological diagnosis of hantavirus infections by an enzyme-linked immunosorbent assay based on detection of immunoglobulin G and M responses to recombinant nucleocapsid proteins of five viral serotypes. J. Clin. Microbiol. 35, 1122-1130 (1997).
49. A. R. Trombley, L. Wachter, J. Garrison, V. A. Buckley-Beason, J. Jahrling, L. E. Hensley, R. J. Schoepp, D. A. Norwood, A. Goba, J. N. Fair, D. A. Kulesh, Comprehensive panel of real-time TaqMan polymerase chain reaction assays for detection and absolute quantification of filoviruses, arenaviruses, and New World hantaviruses. Am. J. Trop. Med. Hyg. 82, 954-960 (2010).
50. National Research Council, Guide for the Care and Use of Laboratory Animals (National Academies Press, Washington, DC, ed. 8, 2011).